Coldstream Capital Management Inc. Acquires 6,227 Shares of AbbVie Inc. $ABBV

Coldstream Capital Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 9.3% during the second quarter, HoldingsChannel reports. The firm owned 72,832 shares of the company’s stock after purchasing an additional 6,227 shares during the period. Coldstream Capital Management Inc.’s holdings in AbbVie were worth $13,519,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. FF Advisors LLC lifted its holdings in AbbVie by 3.6% during the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after buying an additional 53 shares during the period. Landaas & Co. WI ADV increased its holdings in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock valued at $920,000 after acquiring an additional 53 shares during the period. Private Management Group Inc. raised its position in shares of AbbVie by 1.9% in the 1st quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock worth $616,000 after acquiring an additional 54 shares in the last quarter. LifeSteps Financial Inc. lifted its stake in shares of AbbVie by 0.7% during the 2nd quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock worth $1,366,000 after purchasing an additional 54 shares during the last quarter. Finally, Silicon Valley Capital Partners boosted its position in AbbVie by 10.8% during the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock valued at $118,000 after purchasing an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 2.9%

Shares of ABBV stock opened at $236.12 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market capitalization of $417.31 billion, a PE ratio of 112.44, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock’s 50-day simple moving average is $226.81 and its 200-day simple moving average is $205.35.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.9%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HSBC set a $225.00 target price on shares of AbbVie in a report on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Bank of America lifted their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup decreased their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average target price of $241.85.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.